The global market for Pirfenidone API was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Pirfenidone(CAS锛�53179-13-8) is a medication used for the treatment of idiopathic pulmonary fibrosis.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pirfenidone API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pirfenidone API.
The Pirfenidone API market size, estimations, and forecasts are provided in terms of output/shipments (Kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Pirfenidone API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pirfenidone API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, production, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Mylan
Apotex Pharmachem
Aurobindo Pharma Limited
Chemeca Drugs
CHEMO
Glenmark Pharmaceuticals
Hetero Drugs
HONOUR LAB LTD
Jubilant Generics
Laurus Labs
Lupin Ltd
Micro Labs Limited
NEWEDGE Overseas
Optimus Pharma
Raks Pharma
Shilpa Medicare
SMS Pharmaceuticals
Veranova
Signa S.A. de C.V.
Guangzhou Tosun Pharmaceutical
by Type
Above 98 %
Above 99 %
by Application
Tablets
Capsules
Others
Production by Region
North America
Europe
China
India
Mexico
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe
Latin America, Middle East & Africa
Mexico
Brazil
Turkey
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pirfenidone API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Production/output, value of Pirfenidone API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 4: Consumption of Pirfenidone API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 5: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Pirfenidone API 麻豆原创 Overview
1.1 Product Definition
1.2 Pirfenidone API by Type
1.2.1 Global Pirfenidone API 麻豆原创 Value Growth Rate Analysis by Type: 2024 VS 2031
1.2.2 Above 98 %
1.2.3 Above 99 %
1.3 Pirfenidone API by Application
1.3.1 Global Pirfenidone API 麻豆原创 Value Growth Rate Analysis by Application: 2024 VS 2031
1.3.2 Tablets
1.3.3 Capsules
1.3.4 Others
1.4 Global 麻豆原创 Growth Prospects
1.4.1 Global Pirfenidone API Production Value Estimates and Forecasts (2020-2031)
1.4.2 Global Pirfenidone API Production Capacity Estimates and Forecasts (2020-2031)
1.4.3 Global Pirfenidone API Production Estimates and Forecasts (2020-2031)
1.4.4 Global Pirfenidone API 麻豆原创 Average Price Estimates and Forecasts (2020-2031)
1.5 Assumptions and Limitations
2 麻豆原创 Competition by Manufacturers
2.1 Global Pirfenidone API Production 麻豆原创 Share by Manufacturers (2020-2025)
2.2 Global Pirfenidone API Production Value 麻豆原创 Share by Manufacturers (2020-2025)
2.3 Global Key Players of Pirfenidone API, Industry Ranking, 2023 VS 2024
2.4 Global Pirfenidone API 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.5 Global Pirfenidone API Average Price by Manufacturers (2020-2025)
2.6 Global Key Manufacturers of Pirfenidone API, Manufacturing Base Distribution and Headquarters
2.7 Global Key Manufacturers of Pirfenidone API, Product Offered and Application
2.8 Global Key Manufacturers of Pirfenidone API, Date of Enter into This Industry
2.9 Pirfenidone API 麻豆原创 Competitive Situation and Trends
2.9.1 Pirfenidone API 麻豆原创 Concentration Rate
2.9.2 Global 5 and 10 Largest Pirfenidone API Players 麻豆原创 Share by Revenue
2.10 Mergers & Acquisitions, Expansion
3 Pirfenidone API Production by Region
3.1 Global Pirfenidone API Production Value Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
3.2 Global Pirfenidone API Production Value by Region (2020-2031)
3.2.1 Global Pirfenidone API Production Value by Region (2020-2025)
3.2.2 Global Forecasted Production Value of Pirfenidone API by Region (2026-2031)
3.3 Global Pirfenidone API Production Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
3.4 Global Pirfenidone API Production Volume by Region (2020-2031)
3.4.1 Global Pirfenidone API Production by Region (2020-2025)
3.4.2 Global Forecasted Production of Pirfenidone API by Region (2026-2031)
3.5 Global Pirfenidone API 麻豆原创 Price Analysis by Region (2020-2025)
3.6 Global Pirfenidone API Production and Value, Year-over-Year Growth
3.6.1 North America Pirfenidone API Production Value Estimates and Forecasts (2020-2031)
3.6.2 Europe Pirfenidone API Production Value Estimates and Forecasts (2020-2031)
3.6.3 China Pirfenidone API Production Value Estimates and Forecasts (2020-2031)
3.6.4 India Pirfenidone API Production Value Estimates and Forecasts (2020-2031)
3.6.5 Mexico Pirfenidone API Production Value Estimates and Forecasts (2020-2031)
4 Pirfenidone API Consumption by Region
4.1 Global Pirfenidone API Consumption Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
4.2 Global Pirfenidone API Consumption by Region (2020-2031)
4.2.1 Global Pirfenidone API Consumption by Region (2020-2025)
4.2.2 Global Pirfenidone API Forecasted Consumption by Region (2026-2031)
4.3 North America
4.3.1 North America Pirfenidone API Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.3.2 North America Pirfenidone API Consumption by Country (2020-2031)
4.3.3 U.S.
4.3.4 Canada
4.4 Europe
4.4.1 Europe Pirfenidone API Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.4.2 Europe Pirfenidone API Consumption by Country (2020-2031)
4.4.3 Germany
4.4.4 France
4.4.5 U.K.
4.4.6 Italy
4.4.7 Russia
4.5 Asia Pacific
4.5.1 Asia Pacific Pirfenidone API Consumption Growth Rate by Region: 2020 VS 2024 VS 2031
4.5.2 Asia Pacific Pirfenidone API Consumption by Region (2020-2031)
4.5.3 China
4.5.4 Japan
4.5.5 South Korea
4.5.6 China Taiwan
4.5.7 Southeast Asia
4.5.8 India
4.6 Latin America, Middle East & Africa
4.6.1 Latin America, Middle East & Africa Pirfenidone API Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.6.2 Latin America, Middle East & Africa Pirfenidone API Consumption by Country (2020-2031)
4.6.3 Mexico
4.6.4 Brazil
4.6.5 Turkey
4.6.6 GCC Countries
5 Segment by Type
5.1 Global Pirfenidone API Production by Type (2020-2031)
5.1.1 Global Pirfenidone API Production by Type (2020-2025)
5.1.2 Global Pirfenidone API Production by Type (2026-2031)
5.1.3 Global Pirfenidone API Production 麻豆原创 Share by Type (2020-2031)
5.2 Global Pirfenidone API Production Value by Type (2020-2031)
5.2.1 Global Pirfenidone API Production Value by Type (2020-2025)
5.2.2 Global Pirfenidone API Production Value by Type (2026-2031)
5.2.3 Global Pirfenidone API Production Value 麻豆原创 Share by Type (2020-2031)
5.3 Global Pirfenidone API Price by Type (2020-2031)
6 Segment by Application
6.1 Global Pirfenidone API Production by Application (2020-2031)
6.1.1 Global Pirfenidone API Production by Application (2020-2025)
6.1.2 Global Pirfenidone API Production by Application (2026-2031)
6.1.3 Global Pirfenidone API Production 麻豆原创 Share by Application (2020-2031)
6.2 Global Pirfenidone API Production Value by Application (2020-2031)
6.2.1 Global Pirfenidone API Production Value by Application (2020-2025)
6.2.2 Global Pirfenidone API Production Value by Application (2026-2031)
6.2.3 Global Pirfenidone API Production Value 麻豆原创 Share by Application (2020-2031)
6.3 Global Pirfenidone API Price by Application (2020-2031)
7 Key Companies Profiled
7.1 Mylan
7.1.1 Mylan Pirfenidone API Company Information
7.1.2 Mylan Pirfenidone API Product Portfolio
7.1.3 Mylan Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.1.4 Mylan Main Business and 麻豆原创s Served
7.1.5 Mylan Recent Developments/Updates
7.2 Apotex Pharmachem
7.2.1 Apotex Pharmachem Pirfenidone API Company Information
7.2.2 Apotex Pharmachem Pirfenidone API Product Portfolio
7.2.3 Apotex Pharmachem Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.2.4 Apotex Pharmachem Main Business and 麻豆原创s Served
7.2.5 Apotex Pharmachem Recent Developments/Updates
7.3 Aurobindo Pharma Limited
7.3.1 Aurobindo Pharma Limited Pirfenidone API Company Information
7.3.2 Aurobindo Pharma Limited Pirfenidone API Product Portfolio
7.3.3 Aurobindo Pharma Limited Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.3.4 Aurobindo Pharma Limited Main Business and 麻豆原创s Served
7.3.5 Aurobindo Pharma Limited Recent Developments/Updates
7.4 Chemeca Drugs
7.4.1 Chemeca Drugs Pirfenidone API Company Information
7.4.2 Chemeca Drugs Pirfenidone API Product Portfolio
7.4.3 Chemeca Drugs Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.4.4 Chemeca Drugs Main Business and 麻豆原创s Served
7.4.5 Chemeca Drugs Recent Developments/Updates
7.5 CHEMO
7.5.1 CHEMO Pirfenidone API Company Information
7.5.2 CHEMO Pirfenidone API Product Portfolio
7.5.3 CHEMO Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.5.4 CHEMO Main Business and 麻豆原创s Served
7.5.5 CHEMO Recent Developments/Updates
7.6 Glenmark Pharmaceuticals
7.6.1 Glenmark Pharmaceuticals Pirfenidone API Company Information
7.6.2 Glenmark Pharmaceuticals Pirfenidone API Product Portfolio
7.6.3 Glenmark Pharmaceuticals Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.6.4 Glenmark Pharmaceuticals Main Business and 麻豆原创s Served
7.6.5 Glenmark Pharmaceuticals Recent Developments/Updates
7.7 Hetero Drugs
7.7.1 Hetero Drugs Pirfenidone API Company Information
7.7.2 Hetero Drugs Pirfenidone API Product Portfolio
7.7.3 Hetero Drugs Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.7.4 Hetero Drugs Main Business and 麻豆原创s Served
7.7.5 Hetero Drugs Recent Developments/Updates
7.8 HONOUR LAB LTD
7.8.1 HONOUR LAB LTD Pirfenidone API Company Information
7.8.2 HONOUR LAB LTD Pirfenidone API Product Portfolio
7.8.3 HONOUR LAB LTD Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.8.4 HONOUR LAB LTD Main Business and 麻豆原创s Served
7.8.5 HONOUR LAB LTD Recent Developments/Updates
7.9 Jubilant Generics
7.9.1 Jubilant Generics Pirfenidone API Company Information
7.9.2 Jubilant Generics Pirfenidone API Product Portfolio
7.9.3 Jubilant Generics Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.9.4 Jubilant Generics Main Business and 麻豆原创s Served
7.9.5 Jubilant Generics Recent Developments/Updates
7.10 Laurus Labs
7.10.1 Laurus Labs Pirfenidone API Company Information
7.10.2 Laurus Labs Pirfenidone API Product Portfolio
7.10.3 Laurus Labs Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.10.4 Laurus Labs Main Business and 麻豆原创s Served
7.10.5 Laurus Labs Recent Developments/Updates
7.11 Lupin Ltd
7.11.1 Lupin Ltd Pirfenidone API Company Information
7.11.2 Lupin Ltd Pirfenidone API Product Portfolio
7.11.3 Lupin Ltd Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.11.4 Lupin Ltd Main Business and 麻豆原创s Served
7.11.5 Lupin Ltd Recent Developments/Updates
7.12 Micro Labs Limited
7.12.1 Micro Labs Limited Pirfenidone API Company Information
7.12.2 Micro Labs Limited Pirfenidone API Product Portfolio
7.12.3 Micro Labs Limited Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.12.4 Micro Labs Limited Main Business and 麻豆原创s Served
7.12.5 Micro Labs Limited Recent Developments/Updates
7.13 NEWEDGE Overseas
7.13.1 NEWEDGE Overseas Pirfenidone API Company Information
7.13.2 NEWEDGE Overseas Pirfenidone API Product Portfolio
7.13.3 NEWEDGE Overseas Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.13.4 NEWEDGE Overseas Main Business and 麻豆原创s Served
7.13.5 NEWEDGE Overseas Recent Developments/Updates
7.14 Optimus Pharma
7.14.1 Optimus Pharma Pirfenidone API Company Information
7.14.2 Optimus Pharma Pirfenidone API Product Portfolio
7.14.3 Optimus Pharma Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.14.4 Optimus Pharma Main Business and 麻豆原创s Served
7.14.5 Optimus Pharma Recent Developments/Updates
7.15 Raks Pharma
7.15.1 Raks Pharma Pirfenidone API Company Information
7.15.2 Raks Pharma Pirfenidone API Product Portfolio
7.15.3 Raks Pharma Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.15.4 Raks Pharma Main Business and 麻豆原创s Served
7.15.5 Raks Pharma Recent Developments/Updates
7.16 Shilpa Medicare
7.16.1 Shilpa Medicare Pirfenidone API Company Information
7.16.2 Shilpa Medicare Pirfenidone API Product Portfolio
7.16.3 Shilpa Medicare Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.16.4 Shilpa Medicare Main Business and 麻豆原创s Served
7.16.5 Shilpa Medicare Recent Developments/Updates
7.17 SMS Pharmaceuticals
7.17.1 SMS Pharmaceuticals Pirfenidone API Company Information
7.17.2 SMS Pharmaceuticals Pirfenidone API Product Portfolio
7.17.3 SMS Pharmaceuticals Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.17.4 SMS Pharmaceuticals Main Business and 麻豆原创s Served
7.17.5 SMS Pharmaceuticals Recent Developments/Updates
7.18 Veranova
7.18.1 Veranova Pirfenidone API Company Information
7.18.2 Veranova Pirfenidone API Product Portfolio
7.18.3 Veranova Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.18.4 Veranova Main Business and 麻豆原创s Served
7.18.5 Veranova Recent Developments/Updates
7.19 Signa S.A. de C.V.
7.19.1 Signa S.A. de C.V. Pirfenidone API Company Information
7.19.2 Signa S.A. de C.V. Pirfenidone API Product Portfolio
7.19.3 Signa S.A. de C.V. Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.19.4 Signa S.A. de C.V. Main Business and 麻豆原创s Served
7.19.5 Signa S.A. de C.V. Recent Developments/Updates
7.20 Guangzhou Tosun Pharmaceutical
7.20.1 Guangzhou Tosun Pharmaceutical Pirfenidone API Company Information
7.20.2 Guangzhou Tosun Pharmaceutical Pirfenidone API Product Portfolio
7.20.3 Guangzhou Tosun Pharmaceutical Pirfenidone API Production, Value, Price and Gross Margin (2020-2025)
7.20.4 Guangzhou Tosun Pharmaceutical Main Business and 麻豆原创s Served
7.20.5 Guangzhou Tosun Pharmaceutical Recent Developments/Updates
8 Industry Chain and Sales Channels Analysis
8.1 Pirfenidone API Industry Chain Analysis
8.2 Pirfenidone API Raw Material Supply Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.3 Pirfenidone API Production Mode & Process Analysis
8.4 Pirfenidone API Sales and 麻豆原创ing
8.4.1 Pirfenidone API Sales Channels
8.4.2 Pirfenidone API Distributors
8.5 Pirfenidone API Customer Analysis
9 Pirfenidone API 麻豆原创 Dynamics
9.1 Pirfenidone API Industry Trends
9.2 Pirfenidone API 麻豆原创 Drivers
9.3 Pirfenidone API 麻豆原创 Challenges
9.4 Pirfenidone API 麻豆原创 Restraints
10 Research Findings and Conclusion
11 Methodology and Data Source
11.1 Methodology/Research Approach
11.1.1 Research Programs/Design
11.1.2 麻豆原创 Size Estimation
11.1.3 麻豆原创 Breakdown and Data Triangulation
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Author List
11.4 Disclaimer
Mylan
Apotex Pharmachem
Aurobindo Pharma Limited
Chemeca Drugs
CHEMO
Glenmark Pharmaceuticals
Hetero Drugs
HONOUR LAB LTD
Jubilant Generics
Laurus Labs
Lupin Ltd
Micro Labs Limited
NEWEDGE Overseas
Optimus Pharma
Raks Pharma
Shilpa Medicare
SMS Pharmaceuticals
Veranova
Signa S.A. de C.V.
Guangzhou Tosun Pharmaceutical
听
听
*If Applicable.
